Compare Incyte Corporation (INCY) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs First Trust Cloud Computing ETF — how do they compare? Incyte Corporation trades at $113.14 (market cap $22.85B), while First Trust Cloud Computing ETF trades at $173.83 (market cap $3.47B). The key difference: Incyte Corporation is far larger — about 6.6× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and First Trust Cloud Computing ETF for 84 Days on average.
| INCY | SKYY | |
|---|---|---|
Market Cap | $22.85B | $3.47B |
Volume | 1,927,029 | 176,159 |
Sector | Health | — |
52-Week High | $129.93 | $171.01 |
52-Week Low | $83.80 | $104.16 |
Typical Hold Time | 33 Days | 84 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
SKYY (First Trust Cloud Computing ETF) trades at $171.75, up 0.57% today and recently hitting a new 52-week high. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF benefits from strong secular trends in cloud computing and AI infrastructure spending, with recent news highlighting institutional position adjustments and positive sector outlook.
The outlook remains positive given cloud computing's growth trajectory and AI-driven demand, though valuation metrics are unavailable for analysis. Risks include sector concentration and market volatility. Institutional activity shows mixed signals with some trimming positions while sector analysts maintain optimistic coverage on cloud computing infrastructure growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
